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Abstract
Background: Ficolin-mediated activation of the lectin pathway of complement contributes to the complement-
independent inflammatory processes of traumatic brain injury. Lower serum ficolin-3 levels have been demonstrated to
be highly associated with unfavorable outcome after ischemic stroke. This prospective observatory study was designed
to investigate the relationships between serum ficolin-3 levels and injury severity and clinical outcomes after severe
traumatic brain injury.
Methods: Serum ficolin-3 levels of 128 patients and 128 healthy controls were measured by sandwich immunoassays.
An unfavorable outcome was defined as Glasgow Outcome Scale score of 1–3. Study endpoints included mortality at
1 week and 6 months and unfavorable outcome at 6 months after head trauma. Injury severity was assessed by
Glasgow Coma Scale score. Multivariate logistic models were structured to evaluate the relationships between
serum ficolin-3 levels and study endpoints and injury severity.
Results: Compared with the healthy controls, serum ficolin-3 levels on admission were statistically decreased in
patients with severe traumatic brain injury. Serum ficolin-3 levels were independently correlated with Glasgow
Coma Scale scores. Ficolin-3 was also identified as an independent prognostic predictor for 1-week mortality,
6-month mortality, and 6-month unfavorable outcome. Under receiver operating characteristics curves, ficolin-3
has similar prognostic predictive values for all study endpoints compared with Glasgow Coma Scale scores.
Conclusions: It was proposed that lower serum ficolin-3 levels, correlated with injury severity, had the potential
to be the useful, complementary tool to predict short- or long-term clinical outcomes after severe traumatic
brain injury.
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Background
Severe traumatic brain injury (STBI) is a serious public
health problem [1–3]. Outcome prediction is relevant
for both clinical practice and research of STBI [4–6].
Low Glasgow Coma Scale (GCS) scores are associated
highly with poor clinical outcomes of STBI patients [7–9].
In recent years, the application of biomarkers identified in
the peripheral blood has shown potential clinical utility in
neurointensive care as diagnostic, prognostic, and moni-
toring adjuncts [10–12]. Identifying sensitive and reliable
biomarkers associated with patient outcome may improve
our understanding of structural brain damage or under-
lying cellular pathogenesis and regenerative mechanisms
after brain trauma. This information can be used to guide
future basic and clinical research, therefore improving
patient care and outcomes [13, 14].
The complement system is an integral part of the innate
immune system and inflammation [15–17]. Three distinct
pathways constitute the complement system: the classical
pathway, the alternative pathway, and the lectin pathway
[18]. The C1 complex initiates the classical pathway upon
recognition of immune complexes and dying host cells
[19]. The alternative pathway is spontaneously activated by
C3 hydrolysis, but it has also been reported that properdin,
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a stabilizer of the alternative pathway convertase [20], is
capable of initiating the complement cascade [21]. The fico-
lins and mannose-binding lectin (MBL) in association with
MBL/ficolin-associated serine proteases (MASPs) are the
initiator molecules of the lectin pathway. Three MASPs
(−1, −2, and −3) have been described so far, and the current
notion is that MASP-2 is the main lectin pathway activator.
Upon recognition of pathogen-associated molecular
patterns or altered self by MBL and the ficolins, the as-
sociated proteases cleave C4 and C2, hereby activating
the complement cascade which ultimately leads to the
formation of the terminal complement complex [22].
Various studies have revealed particularly novel find-
ings on the wide-ranging involvement of complement
in neural development, synapse elimination, and matur-
ation of neural networks, as well as the progression of
pathology in a range of acute and chronic neurodegen-
erative disorders [23–26].
A traumatic impact to the brain induces an intracra-
nial inflammatory response, which consequently leads to
the development of brain edema and delayed neuronal
death [27–29]. Evidence from experimental, clinical, and
in vitro studies highlights an important role for ficolin-
mediated activation of the lectin pathway of complement
in contributing to inflammation within the injured brain
[30–32]. To date, three different ficolins (−1, −2, and −3)
derived respectively from the genes FCN1, FCN2, and
FCN3 have been described in humans [33]. Ficolin-3
was firstly identified as a serum glycoprotein that reacted
with autoantibodies from patients with systemic lupus
erythematosus [34]. Ficolin-3 is proved to be the pre-
dominant plasma molecule and the greatest complement-
activating capacity among the lectin pathway initiators
[35–40]. Thus, it may possess the strongest potential to be
a prognostic or diagnostic biomarker. Recently, lower
serum ficolin-3 levels have been demonstrated to be highly
associated with the severity and unfavorable outcome after
acute ischemic stroke [41]. Moreover, low levels of plasma
ficolin-3 were related to severity, vasospasm, and cerebral
ischemia of aneurysmal subarachnoid hemorrhage [42].
Hence, we further investigated the ability of ficolin-3 to




This is a prospective observatory study conducted dur-
ing the period of 3 years from July 2011 to July 2014 at
the Sanmen People’s Hospital, Zhejiang Province, China.
This study included the patients with isolated head
trauma and postresuscitation GCS score of 8 or less. Ex-
clusion criteria were infectious diseases; fever within re-
cent 1 month before head trauma; an elevated white blood
cell count; positive chest X-ray, less than 18 years of age;
admission time >6 h; previous head trauma; neurological
disease including ischemic or hemorrhagic stroke; use of
antiplatelet or anticoagulant medication; and the presence
of other prior systemic diseases including diabetes melli-
tus, hypertension, uremia, liver cirrhosis, malignancy, and
chronic heart or lung disease.
Control subjects were recruited from volunteers who
attended the Sanmen People’s Hospital for healthy
examination between July 2011 and July 2014. They
showed normal blood and biochemical laboratory tests,
namely differential blood count, hemoglobin level, total
serum proteins, liver function tests, erythrocytes sedimen-
tation rate, kidney function tests, and C-reactive proteins
as well as were medically tested by a specialist and found
free of any other medical illness.
The study was approved by the Human Investigations
Committee at the Sanmen People’s Hospital, and written
informed consent was obtained from the healthy con-
trols and the legal guardians of STBI patients. This study
was registered in ClinicalTrials.gov (NCT02510573) on
22 July 2015 by Xiong-Wei Gao.
Assessment
Head trauma severity was assessed using initial postre-
suscitation GCS score. All computerized tomography
(CT) scans were performed according to the neuroradi-
ology department protocol. Investigators who read them
were blinded to clinical information. Abnormal cisterns,
midline shift >5 mm, and subarachnoid hemorrhage
(SAH) were recorded on initial CT scan. CT classifica-
tion was performed using Traumatic Coma Data Bank
criteria on initial postresuscitation CT scan according to
the method of Marshall et al. Participants were followed
up until death or completion of 6 months after head
trauma. Clinical outcome included 1-week mortality,
6-month mortality, and 6-month functional outcome.
Using structure telephone interviews, follow-up was
performed by one doctor who was blinded to clinical
information.
Immunoassay methods
Venous blood was drawn from patients on admission
and from healthy controls at study entry. Serum was fro-
zen at −70 °C until assayed. Serum ficolin-3 concentration
was determined by enzyme-linked immunosorbent assay
(Hycult Biotech, the Netherlands). The intra-assay and
inter-assay variations were 3.8 and 5.9 %, respectively. All
determinations were run in duplicates. The persons carry-
ing out the assays were completely blinded to the clinical
information.
Statistical analysis
The results were reported as counts (percentage) for the
categorical variables, mean ± standard deviation if normally
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distributed, and median (interquartile range) if not nor-
mally distributed for the continuous variables. Comparisons
were made by using (1) chi-square test or Fisher’s exact test
for categorical data, (2) Student’s t test for continuous nor-
mally distributed variables, and (3) the Mann–Whitney U
test for continuous non-normally distributed variables.
Correlations were analyzed by Spearman’s correlation
coefficient or Pearson’s correlation coefficient and then
followed by a multivariate linear regression.
The relations of ficolin-3 levels to clinical outcomes
were assessed in a logistic-regression model with calcu-
lated odds ratio (OR) and 95 % confidence interval (CI).
For multivariate analysis, we included the significantly
different outcome predictors as assessed in univariate
analysis. Under receiver operating characteristic (ROC)
curve, the area under curve (AUC) was calculated to
assess the predictive performance of ficolin-3 levels for
clinical outcomes. A combined logistic-regression model
was configured to estimate the additive benefit of ficolin-3
levels to GCS scores.
Statistical analysis was performed with SPSS 19.0 (SPSS
Inc., Chicago, IL, USA) and MedCalc 9.6.4.0. (MedCalc
Software, Mariakerke, Belgium). A P value of less than
0.05 was considered statistically significant.
Results
Study populations’ characteristics
During the study period, 164 patients were admitted to
our emergency department with an isolated severe head
trauma diagnosis. Of these, 36 patients were excluded
because of the following reasons. Five cases had neuro-
logical diseases; five cases had infectious diseases; two
cases, fever within recent 1 month; four cases, elevated
white blood cell count; four cases, admission >6 h; four
cases, the presence of other systemic diseases; two cases,
previous head trauma; three cases, positive chest X-ray;
two cases, less than 18 years of age; two cases, missing of
follow-up; and four cases, use of antiplatelet or anticoagu-
lant medication. Finally, 128 patients were included in the
analysis.
This group of patients, consisting of 80 men and 48
women, had a mean age of 42.5 ± 15.6 years. Median ini-
tial postresuscitation GCS scores were 5 (3). Sixty-two
patients (48.4 %) had unreactive pupils on admission; 58
patients (45.3 %), CT classification 5 or 6; 60 patients
(46.9 %), abnormal cisterns on initial CT scan; 65 patients
(50.8 %), midline shift >5 mm on initial CT scan; 70 pa-
tients (54.7 %), the presence of traumatic subarachnoid
hemorrhage on initial CT scan; and 58 patients (45.3 %),
intracranial surgery in the first 24 h. The mean admission
time was 2.5 ± 1.3 h; the mean plasma-sampling time,
3.8 ± 1.6 h; the mean systolic arterial pressure, 129.9 ±
27.5 mmHg; the mean diastolic arterial pressure, 77.5 ±
17.9 mmHg; the mean value of mean arterial pressure
96.5 ± 18.4 mmHg; the mean plasma C-reactive protein
levels, 7.9 ± 3.2 mg/L; and the mean blood glucose levels,
11.1 ± 3.9 mmol/L.
Control group, consisting of 128 healthy individuals,
included 83 men and 45 women and had a mean age of
42.2 ± 16.4 years. Differences in gender and age were not
shown to be statistically significant between control group
and patients.
Change of serum ficolin-3 levels
Just as shown in Fig. 1, the admission serum ficolin-3
levels were significantly lower in all patients than in healthy
controls, in patients dying than in patients alive within
1 week, in patients dying than in patients alive within
6 months, and in patients with unfavorable outcome than
in patients with favorable outcome within 6 months.
Correlation analysis
Just as shown in Table 1, serum ficolin-3 levels were
highly associated with initial postresuscitation GCS scores,
pupils unreactive on admission, CT classification 5 or 6,
abnormal cisterns on initial CT scan, midline shift >5 mm
on initial CT scan, the presence of traumatic SAH on ini-
tial CT scan, intracranial surgery in the first 24-h blood
glucose level, and plasma C-reactive protein levels. A
multivariate linear regression demonstrated that serum
ficolin-3 levels were still highly associated with GCS scores
(t = 4.994, P < 0.001) and plasma C-reactive protein levels
(t = −3.005, P = 0.003) in Fig. 2.
Prediction of 1-week mortality
In Table 2, serum ficolin-3 levels and other variables
were highly associated with 1-week mortality of patients
with STBI. A multivariate analysis demonstrated that
GCS scores (OR 0.298, 95 % CI 0.138–0.646, P < 0.001)
and serum ficolin-3 levels (OR 0.821, 95 % CI 0.704–0.958,
P < 0.001) were the independent predictors for 1-week
mortality of patients.
Serum ficolin-3 levels statistically significantly predicted
1-week mortality of patients under ROC curve and a cut-
off value of <13.3 μg/mL predicted the prognosis with sen-
sitivity of 85.0 % and specificity of 76.9 %. Table 3 shows
that the AUC of the serum ficolin-3 levels was similar to
that of GCS scores for prediction of 1-week mortality of
the patients. In a combined logistic-regression model,
serum ficolin-3 levels improved the AUC of GCS scores,
but the difference was not statistically significant.
Prediction of 6-month mortality
In Table 2, serum ficolin-3 levels and other variables were
highly associated with 6-month mortality of patients with
STBI. A multivariate analysis demonstrated that GCS
scores (OR 0.408, 95 % CI 0.271–0.613, P < 0.001) and
serum ficolin-3 levels (OR 0.847, 95 % CI 0.756–0.950,
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P < 0.001) were the independent predictors for 6-month
mortality of patients.
Serum ficolin-3 levels statistically significantly predicted
6-month mortality of patients under ROC curve, and a
cutoff value of <13.4 μg/mL predicted the prognosis with
sensitivity of 70.0 % and specificity of 83.0 %. Table 3
shows that the AUC of the serum ficolin-3 levels was simi-
lar to that of GCS scores for prediction of 6-month mor-
tality of the patients. In a combined logistic-regression
model, serum ficolin-3 levels improved the AUC of GCS
scores, but the difference was not statistically significant.
Prediction of 6-month unfavorable outcome
In Table 2, serum ficolin-3 levels and other variables were
highly associated with 6-month unfavorable outcome of
patients with STBI. A multivariate analysis demonstrated
that GCS scores (OR 0.460, 95 % CI 0.336–0.632, P <
0.001) and serum ficolin-3 levels (OR 0.845, 95 % CI
0.758–0.942, P < 0.001) were the independent predictors
for 6-month unfavorable outcome of patients.
Serum ficolin-3 levels statistically significantly pre-
dicted 6-month unfavorable outcome of patients under
ROC curve, and a cutoff value of <18.0 μg/mL predicted
the prognosis with sensitivity of 89.1 % and specificity of
60.9 %. Table 3 shows that the AUC of the serum
ficolin-3 levels was similar to that of GCS scores for pre-
diction of 6-month unfavorable outcome of the patients.
In a combined logistic-regression model, serum ficolin-3
levels improved the AUC of GCS scores, but the difference
was not statistically significant.
Discussion
To our best knowledge, the current study, for the first
time, investigated the serum ficolin-3 levels after STBI.
Its main findings were that STBI patients had decreased
Table 1 The factors correlated with serum ficolin-3 levels in
patients with severe traumatic brain injury
Characteristics r value P value
Sex (male/female) 0.092 0.303
Age (years) 0.046 0.606
Initial postresuscitation GCS score 0.521 <0.001
Pupils unreactive on admission −0.414 <0.001
CT classification 5 or 6 −0.189 0.033
Abnormal cisterns on initial CT scan −0.300 0.001
Midline shift >5 mm on initial CT scan −0.323 <0.001
Presence of traumatic SAH on initial CT scan −0.303 0.001
Intracranial surgery in the first 24 h −0.245 0.005
Admission time (h) 0.090 0.310
Plasma-sampling time (h) 0.067 0.450
Systolic arterial pressure (mmHg) 0.127 0.152
Diastolic arterial pressure (mmHg) 0.120 0.179
Mean arterial pressure (mmHg) 0.132 0.137
Plasma C-reactive protein levels (mg/L) −0.430 <0.001
Blood glucose levels (mmol/L) −0.285 <0.001
Bivariate correlations were assessed by Spearman’s or Pearson’s correlation
coefficient
GCS Glasgow Coma Scale, CT computerized tomography, SAH subarachnoid
hemorrhage
Fig. 1 Graph showing change of serum ficolin-3 levels after severe traumatic brain injury
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serum ficolin-3 levels compared with healthy controls;
serum ficolin-3 levels were independently associated with
GCS scores and plasma C-reactive protein levels; and
ficolin-3 was identified as an independent prognostic pre-
dictor and had high predictive value.
In agreement with previous reported data regarding
acute ischemic stroke and aneurysmal subarachnoid
hemorrhage [41, 42], the decreased serum ficolin-3 levels
were found within 6 h after STBI in the current study. In
ischemic stroke, the decreased serum concentration of
Fig. 2 Graph showing the relationships between serum ficolin-3 levels and Glasgow Coma Scale scores as well as between serum ficolin-3 levels
and plasma C-reactive protein levels after severe traumatic brain injury
Table 2 The factors associated with poor clinical outcomes in patients with severe traumatic brain injury










outcome (n = 64)
Favorable
outcome (n = 64)
P value
Sex (male/female) 13/7 67/41 0.801 27/13 53/35 0.431 44/20 36/28 0.144
Age (years) 45.0 ± 14.5 42.1 ± 15.8 0.440 43.8 ± 15.5 41.9 ± 15.7 0.522 44.6 ± 16.0 40.4 ± 15.1 0.132
Initial postresuscitation
GCS score
3 (1) 6 (4) <0.001 3 (1) 6 (3) <0.001 4 (2) 7 (3) <0.001
Pupils unreactive on
admission
18 (90.0 %) 44(40.7 %) <0.001 32 (80.0 %) 30 (34.1 %) <0.001 43 (80.0 %) 19 (34.1 %) <0.001
CT classification 5 or 6 15 (75.0 %) 43 (39.8 %) 0.004 25 (62.5 %) 33 (37.5 %) 0.008 36 (56.3 %) 22 (34.4 %) 0.013
Abnormal cisterns on
initial CT scan
18 (90.0 %) 42(38.9 %) <0.001 29 (72.5 %) 31(35.2 %) <0.001 40 (62.5 %) 20(31.3 %) <0.001
Midline shift >5 mm on
initial CT scan
17 (85.0 %) 48 (44.4 %) 0.001 30 (75.0 %) 35(39.8 %) <0.001 42 (65.6 %) 23(35.9 %) 0.001
Presence of traumatic
SAH on initial CT scan
16 (80.0 %) 54(50.0 %) 0.013 29 (72.5 %) 41(46.6 %) 0.006 41 (64.1 %) 29 (45.3 %) 0.033
Intracranial surgery in
the first 24 h
12 (60.0 %) 46 (42.6 %) 0.151 21 (52.2 %) 37 (42.1 %) 0.271 31 (48.4 %) 27(42.2 %) 0.478
Admission time (h) 2.3 ± 0.9 2.5 ± 1.3 0.446 2.3 ± 0.9 2.5 ± 1.4 0.384 2.3 ± 1.1 2.6 ± 1.4 0.125
Plasma-sampling time (h) 4.2 ± 1.2 3.7 ± 1.6 0.183 3.7 ± 1.2 3.8 ± 1.7 0.627 3.6 ± 1.5 3.9 ± 1.6 0.220
Systolic arterial pressure
(mmHg)
139.1 ± 22.6 128.2 ± 28.0 0.105 126.7 ± 30.7 131.4 ± 25.9 0.370 126.4 ± 31.2 133.5 ± 22.9 0.146
Diastolic arterial pressure
(mmHg)
81.7 ± 12.6 76.7 ± 18.7 0.255 77.6 ± 16.5 77.4 ± 18.6 0.942 75.5 ± 20.0 79.4 ± 15.5 0.219
Mean arterial pressure
(mmHg)
102.7 ± 15.1 95.4 ± 18.8 0.100 99.0 ± 16.5 95.4 ± 19.2 0.311 95.6 ± 20.4 97.4 ± 16.3 0.572
Plasma C-reactive protein
level (mg/L)
11.1 ± 2.3 7.3 ± 3.1 <0.001 10.3 ± 4.1 6.8 ± 2.0 <0.001 9.3 ± 3.7 6.5 ± 1.9 <0.001
Blood glucose level
(mmol/L)
12.7 ± 4.0 9.6 ± 3.1 0.002 13.6 ± 4.1 10.0 ± 3.3 <0.001 12.7 ± 4.0 9.6 ± 3.1 <0.001
Serum ficolin-3 levels
(μg/mL)
10.1 ± 4.1 16.9 ± 5.6 <0.001 11.4 ± 4.4 17.8 ± 5.5 <0.001 12.7 ± 4.5 19.0 ± 5.5 <0.001
Numerical variables were presented as mean ± standard deviation or median (interquartile range) and analyzed by unpaired Student’s t test or Mann–Whitney
U test. Categorical variables were expressed as counts (percentage) and analyzed by chi-square test or Fisher’s exact test
GCS Glasgow Coma Scale, CT computerized tomography, SAH subarachnoid hemorrhage
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ficolin-3 could be observed in the very early phase and
remained unchanged during the next 3–4 days [41].
Since ficolin-3 has been shown to be involved in the se-
questration of dying host cells [43], it seems reasonable
to surmise that this decrease of serum ficolin-3 levels
should be due to consumption through the binding of
the molecules to the apoptotic and necrotic cells [44],
indicating that the decreased levels in sera during the
acute phase of head trauma could be related to the
acute traumatic event.
In ischemic stroke, serum ficolin-3 levels are inversely
correlated with the severity of stroke indicated by the
National Institute of Health stroke scale on admission
and the concentrations of S100b, an indicator of the size
of cerebral infarct [41]. In aneurysmal subarachnoid
hemorrhage, low levels of plasma ficolin-3 are related
to hemorrhagic severity assessed using the World Fed-
eration of Neurosurgical Societies grading scale, vaso-
spasm defined as neuro-worsening with angiographic
confirmation of vessel narrowing and cerebral ischemia
defined as hypodense lesion on CT scan performed be-
fore discharge [42]. This study demonstrated that the
decreased serum ficolin-3 levels were highly associated
with trauma severity reflected by GCS scores. Hence,
the selective ability for complement activation after the
binding of ficolin-3 to dying cells might be responsible
for the selective clinical correlation with the levels of
this protein [45], indicating serum fiction-3 levels could
reflect the severity of brain injury.
The complement activation has been confirmed as a
crucial inflammatory component in a lot of diseases
[36, 37]. An increasing number of clinical researches
have addressed the potential role of ficolin-3 in various
inflammatory status and diseases like diabetic peripheral
neuropathy [46], diabetic microvascular complication [47],
and pre-eclampsia [48]. The current study found that
serum ficolin-3 levels were associated negatively with
systemic inflammatory severity indicated by plasma C-
reactive protein levels. The decrease in ficolin-3 level
has been confirmed to be accompanied with increased
complement activation [49]. Thus, the increased con-
sumption of ficolin-3 might exacerbate complement ac-
tivation, leading to the inflammation and tissue damage
after head trauma.
Lower serum ficolin-3 levels have been demonstrated
to be highly associated with the severity and unfavorable
outcome after acute ischemic stroke and aneurysmal
subarachnoid hemorrhage [41, 42]. In this study, ficolin-
3 was identified as an independent predictor for long-
term and short-term clinical outcomes including 1-week
mortality, 6-month mortality, and 6-month unfavorable
outcome. We further used the ROC curves to verify the
prognostic predictive values of serum ficolin-3 levels.
Although ficolin-3 did not improve the AUC of GCS
scores under ROC curve, ficolin-3 had similar predictive
performance to the GCS scores. Thus, it is more convin-
cing that ficolin-3 may be a good prognostic predictor
after STBI.
Conclusions
In this study, serum ficolin-3 levels are correlated with
head trauma severity and systemic inflammatory severity,
as well as independently predict short-term and long-term
clinical outcomes of severe TBI. Therefore, it is suggested
that serum ficolin-3 may have the potential to be a good
prognostic predictive biomarker after head trauma.
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AUC area under curve, CI confidence interval, GCS Glasgow Coma Scale, Ref. reference
Pan et al. Journal of Neuroinflammation  (2015) 12:226 Page 6 of 7
Received: 24 August 2015 Accepted: 23 November 2015
References
1. Baguley IJ, Nott MT, Howle AA, Simpson GK, Browne S, King AC, et al.
Late mortality after severe traumatic brain injury in New South Wales: a
multicentre study. Med J Aust. 2012;22:40–5.
2. Frattalone AR, Ling GS. Moderate and severe traumatic brain injury:
pathophysiology and management. Neurosurg Clin N Am. 2013;24:309–19.
3. Zammit C, Knight WA. Severe traumatic brain injury in adults. Emerg Med
Pract. 2013;15:1–28.
4. Bosarge PL, Shoultz TH, Griffin RL, Kerby JD. Stress-induced hyperglycemia is
associated with higher mortality in severe traumatic brain injury. J Trauma
Acute Care Surg. 2015;79:289–94.
5. Daoud H, Alharfi I, Alhelali I, Charyk Stewart T, Qasem H, Fraser DD. Brain
injury biomarkers as outcome predictors in pediatric severe traumatic brain
injury. Neurocrit Care. 2014;20:427–35.
6. Zhang ZY, Zhang LX, Dong XQ, Yu WH, Du Q, Yang DB, et al. Comparison
of the performances of copeptin and multiple biomarkers in long-term
prognosis of severe traumatic brain injury. Peptides. 2014;60:13–7.
7. Fulkerson DH, White IK, Rees JM, Baumanis MM, Smith JL, Ackerman LL,
et al. Analysis of long-term (median 10.5 years) outcomes in children
presenting with traumatic brain injury and an initial Glasgow Coma Scale
score of 3 or 4. J Neurosurg Pediatr. 2015;3:1–10.
8. Gorji MA, Gorji AM, Hosseini SH. Which score should be used in intubated
patients’ Glasgow Coma Scale or full outline of unresponsiveness? Int J Appl
Basic Med Res. 2015;5:92–5.
9. Simon D, Nicol JM, Sabino Da Silva S, Graziottin C, Silveira PC, Ikuta N, et al.
Serum ferritin correlates with Glasgow Coma Scale scores and fatal
outcome after severe traumatic brain injury. Brain Inj. 2015;29:612–7.
10. Wang KY, Yu GF, Zhang ZY, Huang Q, Dong XQ. Plasma high-mobility
group box 1 levels and prediction of outcome in patients with traumatic
brain injury. Clin Chim Acta. 2012;413:1737–41.
11. Xu JF, Liu WG, Dong XQ, Yang SB, Fan J. Change in plasma gelsolin level
after traumatic brain injury. J Trauma Acute Care Surg. 2012;72:491–6.
12. Dong XQ, Huang M, Yang SB, Yu WH, Zhang ZY. Copeptin is associated with
mortality in patients with traumatic brain injury. J Trauma. 2011;71:1194–8.
13. Levin HS, Diaz-Arrastia RR. Diagnosis, prognosis, and clinical management of
mild traumatic brain injury. Lancet Neurol. 2015;14:506–17.
14. Zetterberg H, Blennow K. Fluid markers of traumatic brain injury. Mol Cell
Neurosci. 2015;66:99–102.
15. Nonaka M. Evolution of the complement system. Subcell Biochem.
2014;80:31–43.
16. Gadjeva M. The complement system. Overview. Methods Mol Biol.
2014;1100:1–9.
17. Phieler J, Garcia-Martin R, Lambris JD, Chavakis T. The role of the complement
system in metabolic organs and metabolic diseases. Semin Immunol.
2013;25:47–53.
18. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058–66.
19. Kishore U, Reid KB. C1q: structure, function, and receptors.
Immunopharmacology. 2000;49:159–70.
20. Fearon DT, Austen KF. Properdin: binding to C3b and stabilization of the
C3b-dependent C3 convertase. J Exp Med. 1975;142:856–63.
21. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate
complement activation by binding specific target surfaces and providing a
platform for de novo convertase assembly. J Immunol. 2007;179:2600–8.
22. Thiel S. Complement activating soluble pattern recognition molecules with
collagen-like regions, mannan-binding lectin, ficolins and associated proteins.
Mol Immunol. 2007;44:3875–88.
23. Harvey H, Durant S. The role of glial cells and the complement system in
retinal diseases and Alzheimer’s disease: common neural degeneration
mechanisms. Exp Brain Res. 2014;232:3363–77.
24. Hertle E, Stehouwer CD, van Greevenbroek MM. The complement system in
human cardiometabolic disease. Mol Immunol. 2014;61:135–48.
25. Doni A, Garlanda C, Bottazzi B, Meri S, Garred P, Mantovani A. Interactions of
the humoral pattern recognition molecule PTX3 with the complement
system. Immunobiology. 2012;217:1122–8.
26. Brennan FH, Anderson AJ, Taylor SM, Woodruff TM, Ruitenberg MJ. Complement
activation in the injured central nervous system: another dual-edged
sword? J Neuroinflammation. 2012;9:137.
27. Lozano D, Gonzales-Portillo GS, Acosta S, de la Pena I, Tajiri N, Kaneko Y,
et al. Neuroinflammatory responses to traumatic brain injury: etiology,
clinical consequences, and therapeutic opportunities. Neuropsychiatr Dis
Treat. 2015;11:97–106.
28. Corps KN, Roth TL, McGavern DB. Inflammation and neuroprotection in
traumatic brain injury. JAMA Neurol. 2015;72:355–62.
29. Monaco 3rd EA, Tempel Z, Friedlander RM. Inflammation triggered by
traumatic brain injury may continue to harm the brain for a lifetime.
Neurosurgery. 2013;72:N19–20.
30. Balu R. Inflammation and immune system activation after traumatic brain
injury. Curr Neurol Neurosci Rep. 2014;14:484.
31. Gyoneva S, Ransohoff RM. Inflammatory reaction after traumatic brain injury:
therapeutic potential of targeting cell-cell communication by chemokines.
Trends Pharmacol Sci. 2015;36:471–80.
32. Stahel PF, Morganti-Kossmann MC, Kossmann T. The role of the
complement system in traumatic brain injury. Brain Res Brain Res Rev.
1998;27:243–56.
33. Endo Y, Matsushita M, Fujita T. Role of ficolin in innate immunity and its
molecular basis. Immunobiology. 2007;212:371–9.
34. Hein E, Honore’ C, Skjoedt MO, Munthe-Fog L, Hummelshøj T, Garred P.
Functional analysis of ficolin-3 mediated complement activation. PLoS One.
2010;5:e15443.
35. Kjaer TR, Thiel S, Andersen GR. Toward a structure-based comprehension of
the lectin pathway of complement. Mol Immunol. 2013;56:413–22.
36. Boldt AB, Goeldner I, de Messias-Reason IJ. Relevance of the lectin pathway
of complement in rheumatic diseases. Adv Clin Chem. 2012;56:105–53.
37. Endo Y, Matsushita M, Fujita T. The role of ficolins in the lectin pathway of
innate immunity. Int J Biochem Cell Biol. 2011;43:705–12.
38. Matsushita M, Fujita T. The lectin pathway. Res Immunol. 1996;147:115–8.
39. Gadjeva M, Thiel S, Jensenius JC. The mannan-binding-lectin pathway of the
innate immune response. Curr Opin Immunol. 2001;13:74–8.
40. Nauta AJ, Raaschou-Jensen N, Roos A, Daha MR, Madsen HO, Borrias-Essers
MC, et al. Mannose-binding lectin engagement with late apoptotic and
necrotic cells. Eur J Immunol. 2003;33:2853–63.
41. Füst G, Munthe-Fog L, Illes Z, Széplaki G, Molnar T, Pusch G, et al. Low
ficolin-3 levels in early follow-up serum samples are associated with the
severity and unfavorable outcome of acute ischemic stroke. J
Neuroinflammation. 2011;8:185.
42. Zanier ER, Zangari R, Munthe-Fog L, Hein E, Zoerle T, Conte V, et al.
Ficolin-3-mediated lectin complement pathway activation in patients
with subarachnoid hemorrhage. Neurology. 2014;82:126–34.
43. Jensen ML, Honore C, Hummelshoj T, Hansen BE, Madsen HO, Garred P.
Ficolin-2 recognizes DNA and participates in the clearance of dying host
cells. Mol Immunol. 2007;44:856–65.
44. Yanamadala V, Friedlander RM. Complement in neuroprotection and
neurodegeneration. Trends Mol Med. 2010;16:69–76.
45. Chen H, Lu J, Chen X, Yu H, Zhang L, Bao Y, et al. Low serum levels of the
innate immune component ficolin-3 is associated with insulin resistance and
predicts the development of type 2 diabetes. J Mol Cell Biol. 2012;4:256–7.
46. Zhang X, Hu Y, Shen J, Zeng H, Lu J, Li L, et al. Low levels of ficolin-3 are
associated with diabetic peripheral neuropathy. Acta Diabetol. 2015.
doi:10.1007/s00592-015-0780-6.
47. Fujita T, Hemmi S, Kajiwara M, Yabuki M, Fuke Y, Satomura A, et al.
Complement-mediated chronic inflammation is associated with diabetic
microvascular complication. Diabetes Metab Res Rev. 2013;29:220–6.
48. Halmos A, Rigó Jr J, Szijártó J, Füst G, Prohászka Z, Molvarec A. Circulating
ficolin-2 and ficolin-3 in normal pregnancy and pre-eclampsia. Clin Exp
Immunol. 2012;169:49–56.
49. Prohászka Z, Munthe-Fog L, Ueland T, Gombos T, Yndestad A, Förhécz Z,
et al. Association of ficolin-3 with severity and outcome of chronic heart
failure. PLoS One. 2013;8, e60976.
Pan et al. Journal of Neuroinflammation  (2015) 12:226 Page 7 of 7
